PRECEDO Biobank at ISBER 2024
Release time:
2024-04-09
In April 2024, PRECEDO attended the 25th International Society for Biological and Environmental Repositories (ISBER) Annual Meeting in Melbourne, Australia. Together with biobankers from over 30 countries, we engaged in discussions on the future direction of biobanking for the next 25 years. Among the key emerging trends, “Service Biobank” was identified as a major direction, and our Living Cancer Primary Cell Biobank and its translational platforms received strong recognition from attending experts.
In April 2024, PRECEDO attended the 25th International Society for Biological and Environmental Repositories (ISBER) Annual Meeting in Melbourne, Australia. Together with biobankers from over 30 countries, we engaged in discussions on the future direction of biobanking for the next 25 years. Among the key emerging trends, “Service Biobank” was identified as a major direction, and our Living Cancer Primary Cell Biobank and its translational platforms received strong recognition from attending experts.
About PRECEDO Biobank
PRECEDO Biobank (Human Genetic Resource Preservation License No.: [2022] BC0101) focuses on the establishment and preservation of:
- Patient-derived primary cells
- Organoids
- Patient-derived xenograft (PDX) models
These models are derived from surgical resections, biopsies, and malignant effusions (pleural effusion, ascites) from cancer patients.
Integrated Service Platforms
PRECEDO Biobank serves not only as a repository for sample collection and storage, but also as a platform for translational and clinical services, including:
- Clinical drug sensitivity testing
- Preclinical drug research and evaluation
By integrating high-quality human-derived models with robust analytical platforms, we provide critical data and model support to advance precision medicine for cancer patients and novel drug development for pharmaceutical innovators.
Recent information
